Chinese Drug Developer I-Mab Proceeds With Shanghai Dual Listing
- Board approves STAR board plan; hires CICC for share sale
- I-Mab raised about $114 million in U.S. IPO in Jan. 2020
This article is for subscribers only.
I-Mab is progressing with its dual listing plans on Shanghai’s Nasdaq-style exchange as the drug developer seeks to expand its investor base.
The Chinese company’s board approved the proposed STAR board listing and has hired China International Capital Corp. to work on its initial public offering tutorial, according to a statement Tuesday. The company, which is traded in New York, aims to complete the Shanghai offering next year. It didn’t specify a fundraising target.